NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
ID: 352162Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352162

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) grant, aimed at supporting mid-phase clinical trials of natural products such as botanicals and dietary supplements. The objective is to evaluate optimal doses, formulations, and patient responses, with a requirement for preliminary data demonstrating bioavailability and measurable target engagement. This funding opportunity is crucial for advancing research in natural products, particularly in areas like symptom management and minority health, while excluding trials focused on cancer treatment. Applicants can request up to $350,000 annually for a maximum project period of five years, with the submission deadline set for November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-115-Full-Announcement.html
    PAR-24-115.html
    The National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH) invites applications for mid-phase clinical trials focusing on natural products such as botanicals and dietary supplements through the NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) funding opportunity (PAR-24-115). This initiative seeks to support trials that evaluate optimal doses, formulations, and patient responses, backed by preliminary data demonstrating bioavailability and measurable target engagement. The proposal should exclude single-site efficacy trials and those aimed at cancer treatment. Key application components include a Plan for Enhancing Diverse Perspectives (PEDP), which must be included in submissions, and focus on priority areas such as symptom management and minority health. Funded projects can request budgets up to $350,000 annually, with a maximum project period of five years. The submission process emphasizes the importance of compliance with NIH registration and guidelines, and a well-defined timeline is essential for milestone completion. Applications will undergo a peer review process to assess significance, investigator qualifications, innovation, and the study's approach. The deadline for submission is set for March 2026, with a strong emphasis on ensuring diverse perspectives in research.
    Similar Opportunities
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early phase clinical trials focused on natural products such as botanicals and dietary supplements. This funding opportunity encourages research that rigorously evaluates the effects of these products on specific biological targets, with a total budget limit of $1,050,000 in direct costs available for up to three years of support. The initiative is particularly relevant for addressing health issues like chronic pain and gastrointestinal disorders, emphasizing the importance of diverse research collaborations and methodologies. Interested applicants must comply with NIH grants policies and submit their proposals by November 13, 2026, while also enhancing research diversity through a Plan for Enhancing Diverse Perspectives (PEDP). For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials focused on natural products, such as botanicals and dietary supplements. Applicants are required to submit a comprehensive plan detailing project management, participant recruitment, and clinical trial execution, while also ensuring alignment with NIH standards. This initiative emphasizes the importance of evidence-based research in natural products and mandates the submission of a corresponding Data Coordinating Center (DCC) proposal to oversee data management and analysis. Interested applicants should note that the application deadline is July 15, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For additional details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multi-site feasibility clinical trials of mind and body interventions through the National Center for Complementary and Integrative Health (NCCIH). This R01 research grant invites applications focused on investigating complementary health approaches that utilize physical or psychological therapies, with an emphasis on demonstrating prior feasibility data to support the multi-site approach. The initiative aims to enhance understanding of integrative health interventions, particularly their efficacy and impact on diverse populations and health disparities. Interested applicants can apply for a maximum project budget of $350,000 annually over a period not exceeding three years, with a submission deadline of January 20, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is offering a funding opportunity for feasibility clinical trials focused on mind and body interventions addressing high-priority research topics. The objective is to support R34 planning grants that gather essential data necessary for the design and planning of future full-scale efficacy studies, specifically examining aspects such as intervention acceptability, recruitment strategies, and data collection procedures. This initiative is crucial for advancing research in nonpharmacological approaches to symptom management, particularly relevant in the context of increasing healthcare demands. Interested applicants can apply for grants of up to $450,000 over three years, with a submission deadline of November 13, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-084.html.
    Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth." This initiative encourages the submission of proposals for fully remotely conducted clinical trials aimed at assessing the efficacy of complementary and integrative health interventions, particularly in areas designated as high research priorities by the National Center for Complementary and Integrative Health (NCCIH). The trials must involve no in-person contact between research staff and participants, utilizing mobile health technologies, and applicants are required to provide preliminary data demonstrating the feasibility and safety of their proposed approaches, along with a Plan for Enhancing Diverse Perspectives (PEDP) that will be evaluated during the review process. The application period opens on January 20, 2024, with a submission deadline of February 20, 2026. Interested applicants can find more information and guidance at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.